George Apergis, MD
Pulmonary Disease · Brooklyn, NYNPI 1760657183
Payments from drug & device makers
Across 175 payments — averaging $25.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$926
- Insmed, Inc.$712
- AstraZeneca$575
- Otsuka America Pharmaceutical, Inc.$316
- Boehringer Ingelheim$201
- Mallinckrodt Enterprises LLC$192
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,04690%
- Education$43810%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 35 | $926 |
| Insmed, Inc. | 21 | $712 |
| AstraZeneca | 28 | $575 |
| Otsuka America Pharmaceutical, Inc. | 13 | $316 |
| Boehringer Ingelheim | 8 | $201 |
| Mallinckrodt Enterprises LLC | 6 | $192 |
| Amgen | 8 | $173 |
| Sanofi | 2 | $167 |
| Amarin Pharma, Inc. | 7 | $144 |
| Actelion Pharmaceuticals US, Inc. | 4 | $139 |
| Inogen, Inc. | 6 | $124 |
| Teva Pharmaceuticals USA, Inc. | 5 | $106 |
| Johnson & Johnson | 4 | $75 |
| Verona Pharma, Inc. | 3 | $66 |
| Philips North America LLC | 2 | $63 |
| Electromed, Inc. | 2 | $54 |
| Pfizer | 3 | $53 |
| Collegium Pharmaceutical, Inc. | 2 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $44 |
| Merck | 2 | $41 |
| Circassia Inc. | 2 | $37 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
| Viatris Specialty LLC | 1 | $31 |
| AbbVie | 1 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $23 |
| Gilead | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Urovant Sciences Inc | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$250
- DUPIXENT$136
- Arikayce$116
How this compares
$4,484 in reported general payments places this provider in the 70th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 457 | $184,001 |
| JanuviaSitagliptin Phosphate | 184 | $98,323 |
| XareltoRivaroxaban | 170 | $71,766 |
| RexultiBrexpiprazole | 54 | $59,489 |
| JardianceEmpagliflozin | 111 | $54,843 |
| XifaxanRifaximin | 26 | $32,848 |
| OzempicSemaglutide | 21 | $31,300 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $30,647 |
| MounjaroTirzepatide | 20 | $24,537 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $23,211 |
| TradjentaLinagliptin | 33 | $19,099 |
| EntrestoSacubitril/Valsartan | 35 | $17,455 |
| FarxigaDapagliflozin Propanediol | 16 | $15,248 |
| MyrbetriqMirabegron | 33 | $12,517 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $12,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $53 | $184,001457 claims |
| MerckJanuvia, Janumet | $41 | $110,572195 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $201 | $80,021157 claims |
| Johnson & JohnsonXarelto | $75 | $71,766170 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $316 | $59,48954 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Brilinta, Symbicort | $575 | $51,34485 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta | $926 | $50,56871 claims |
| NovartisEntresto | $19 | $17,45535 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Brooklyn
- Ali El AtatBrooklyn$547K
- Sunil MehraBrooklyn$388K
- Aaliya BurzaBrooklyn$334K
- Xiaojun YanBrooklyn$249K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.